References
- Rabiner S F, Helbert J R, Lopas H, Friedman L H. Evaluation of a stromafree hemoglobin solution for use a plasma expander. J Exp Med 1967; 126: 1127–1142
- Schreiber G B, Busch M P, Kleinman S H, Korelitz J J. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685–1690
- Nakai K, Sekiguchi S. Quality control of stroma-free hemoglobin. Artificial Red Cells, E. Tsuchida. John Wiley & Sons, Chichester 1995; 131–149
- Abe H, Nakai K, Takahashi T A, Sekiguchi S. An inhibition enzyme immunoassay for quantification of blood group antigen in stroma-free hemoglobin. Artif Organs Today 1995; 5: 19–28
- Nakai K, Matsuda N, Ohta T, Amano M, Takahashi T A, Sakuma I, Kitabatake A, Ito S, Nakazato Y, Sekiguchi S. Lysophosphatidylcholine, a component of stromal phospholipids, as a candidate vasoconstrictive factor present in stroma-free hemoglobin. Artif Organs 1994; 18: 198–205
- Nakai K, Matsuda N, Abe H, Kobayashi M, Ikeda H, Morisawa K, Nakachi O, Ishikawa G, Sekiguchi S. Usefulness of a virus removal filter BMM to remove stroma from hemoglobin solutions. Jpn J Artif Organs 1992; 21: 318–322
- Sekiguchi S, Ito K, Kobayashi M, Ikeda H, Tsurumi T, Ishikawa G, Manabe S, Satani M, Yamashiki T. Possibility of hepatitis B virus (HBV) removal from human plasma using regenerated cellulose hollow fiber (BMM). Membrane 1989; 14: 253–261
- Azari M, Ebeling A, Baker R, Burhop K, Camacho T, Estep T, Guzder S, Marshall T, Rohn K, Sarajari R. Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHbTM) for viral inactivation. Artif Cells Blood Substit Immobil Biotechnol 1998; 25: 577–582
- Friedman L I, Stromberg R R, Wagner S J. Reducing the infectivity of blood components-what we have learned. Blood supply: risks, perceptions and prospects for the future, S. T. Nance. American Association of Blood Banks, Bethesda, MD 1994; 139–167
- Azzi A, Ciappi S, Zakvrezeska K, Morfini M, Mariani G, Mannucci P M. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228–230
- Sekiguchi S, Ito K, Kobayashi M, Ikeda H, Manabe S, Tsurumi T, Ishikawa G, Satani M, Yamaguchi K. An attempt to prepare hepatitis B virus (HBV)-free plasma by ultra-filtration using microporous regenerated cellulose hollow fiber. Transfus Sci 1990; 11: 211–216
- Reed L J, Muench H. A simple method of estimating 50 percent endpoints. Am J Hyg 1938; 27: 493–497
- van Kampen E J, Zijlstra W G. Determination of hemoglobin and its derivatives. Adv Clin Chem 1965; 8: 141–187
- Sakata H, Ihara H, Sato S, Kato T, Ikeda H, Sekiguchi S. Efficiency of donor screening for human parvovirus B19 by the RHA method. Vox Sang, (in press)
- Sekiguchi S, Sato S, Kato T. Human parvovirus B19 DNA detected by receptor-mediated hemagglutination assay of pooled plasma for fractionation. Transfusion 1998; 38: 108–109
- Ogata Y, Goto H, Kimura T, Fukui H. Development of Neo Red Cells (NRC) with the enzymatic reduction system of methemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1997; 25: 417–427